After the trial concluded, the executive vice president for Development, Martin Holst Lange said that the company was very pleased with the weight loss demonstrated by the once-daily oral formulation of semaglutide in [treating] obesity . Novo Nordisk reported that the results were consistent with the impacts found with the injectable version of the drug
Some people see a 1 to 2 pound drop, which is usually water weight from eating less rather than actual fat loss
In the treatment of obesity, there is a non-pharmacological aspect necessary to achieve weight loss goals
However, activators of this receptor also are gaining attention due to their ability to protect nerve cells from damage, promote nerve cell growth, and boost the integrity of the blood-brain-barrier, a tight, semi-permeable membrane that controls which substances in the bloodstream can get into the brain
Once levothyroxine is optimized after initial GLP-1 weight loss, hormonal balance usually stabilizes